Physician profile
Michael Yeager
NPI 1952643371
$3,272.06
in general payments reported to CMS, 2019-2025
22 companies · $574 in 2025
The $574 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.48 · 2020: $164 · 2021: $432 · 2022: $771 · 2023: $681 · 2024: $601 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $726.13 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $456.06 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $395.08 | 2020-2025 | Glassia, Hyqvia |
| Shionogi INC | $228.60 | 2020-2024 | Fetroja |
| Regeneron Healthcare Solutions, INC. | $214.64 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.34 | 2021-2024 | Ofev |
| Genzyme Corporation | $158.66 | 2021-2025 | |
| Amgen INC. | $144.11 | 2022-2025 | Tezspire |
| Janssen Pharmaceuticals, INC | $121.84 | 2024 | Xarelto |
| Insmed, INC. | $106.54 | 2020-2025 | Brinsupri, Arikayce |
| Actelion Pharmaceuticals US, INC. | $95.07 | 2024-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $91.92 | 2025 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $81.07 | 2022-2025 | |
| Grifols USA, LLC | $64.87 | 2025 | Prolastin-C Liquid |
| Abbvie INC. | $46.88 | 2022-2023 | Teflaro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $40.30 | 2021-2024 | |
| Baxter Healthcare | $25.61 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Nabriva Therapeutics, Plc | $23.70 | 2020 | |
| Allergan, INC. | $20.39 | 2020 | |
| Merck Sharp & Dohme LLC | $18.81 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.70 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.58 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yeager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.